Valneva SE

6.90 USD
-0.19 (-2.68%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Valneva SE stock is down -15.34% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 2 March’s closed higher than February. 100% of analysts rate it a buy.

About Valneva SE

Valneva SE focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia. It sells its products in the United States, Canada, Germany, Austria, Nordics, other European countries, and internationally.